Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: The REDUCE randomized clinical trial

JAMA

Volumn 309, Issue 21, 2013, Pages 2223-2231

  Leuppi, Jörg D ^a   Schuetz, Philipp ^c   Bingisser, Roland ^a   Bodmer, Michael ^a   Briel, Matthias ^b   Drescher, Tilman ^a   Duerring, Ursula ^a   Henzen, Christoph ^d   Leibbrandt, Yolanda ⁱ   Maier, Sabrina ^a   Miedinger, David ^a   Müller, Beat ^c   Scherr, Andreas ^a   Schindler, Christian ^f   Stoeckli, Rolf ^a   Viatte, Sebastien ^g,i   Von Garnier, Christophe ^h   Tamm, Michael ^a   Rutishauser, Jonas ^e,i  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c CANTONAL HOSPITAL AARAU   (Switzerland)

^d LUZERNER KANTONSSPITAL   (Switzerland)

^e UNIVERSITY OF BASEL   (Switzerland)

^f UNIVERSITY OF BASEL   (Switzerland)

^g UNIVERSITY OF MANCHESTER   (United Kingdom)

^h UNIVERSITY OF BERN   (Switzerland)

ⁱ Hospital Center   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; MEPREDNISONE; PLACEBO; PREDNISONE; STEROID;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EMERGENCY WARD; FEMALE; HOSPITAL ADMISSION; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; TEACHING HOSPITAL; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84878538257     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.5023     Document Type: Article

References (25)

1. Hansel TT, Barnes PJ. New drugs for exacerbations of chronic obstructive pulmonary disease. Lancet. 2009;374(9691):744-755.
2. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925-931. (Pubitemid 41598207)
3. Jochmann A, Neubauer F, Miedinger D, Schafroth S, Tamm M, Leuppi JD. General practitioner's adherence to the COPD GOLD guidelines: baseline data of the Swiss COPD Cohort Study. Swiss Med Wkly. 2010;140:w13053.
4. Jochmann A, Scherr A, Jochmann DC, et al. Impact of adherence to the GOLD guidelines on symptom prevalence, lung function decline and exacerbation rate in the Swiss COPD cohort. Swiss Med Wkly. 2012;142:w13567.
5. Wouters EF. Management of severe COPD. Lancet. 2004;364(9437):883-895.
6. Walters JAE, Wang W, Morley C, Soltani A, Wood-Baker R. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011;(10):CD006897.
7. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD. http://www.goldcopd.org/ guidelines/guidelines-resources.html. Accessed April 18, 2013.
8. Thompson WH, Nielson CP, Carvalho P, Charan NB, Crowley JJ. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med. 1996;154(2 pt 1):407-412. (Pubitemid 26269111)
9. Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet. 1999;354(9177):456- 460. (Pubitemid 29368923)
10. Niewoehner DE, Erbland ML, Deupree RH, et al Department of Veterans Affairs Cooperative Study Group. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 1999;340(25):1941-1947. (Pubitemid 29288269)
11. Aaron SD, Vandemheen KL, Hebert P, et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med. 2003;348(26):2618-2625. (Pubitemid 36741589)
12. Lindenauer PK, Pekow PS, Lahti MC, Lee Y, Benjamin EM, Rothberg MB. Association of corticosteroid dose and route of administration with risk of treatment failure in acute exacerbation of chronic obstructive pulmonary disease. JAMA. 2010;303(23):2359-2367.
13. Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest. 2003;124(2):459-467. (Pubitemid 37000120)
14. Schuetz P, Leuppi JD, Tamm M, et al. Short versus conventional term glucocorticoid therapy in acute exacerbation of chronic obstructive pulmonary disease - the "REDUCE" trial. Swiss Med Wkly. 2010;140:w13109.
15. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106(2):196-204. (Pubitemid 17009877)
16. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932-946. (Pubitemid 38807371)
17. Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG; CONSORT Group. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA. 2012;308(24):2594-2604.
18. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS; GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163(5):1256-1276. (Pubitemid 32378468)
19. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 2000;117(5)(suppl 2):398S-401S. (Pubitemid 30314474)
20. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54(7):581-586. (Pubitemid 29296676)
21. Evans AT, Husain S, Durairaj L, Sadowski LS, Charles-Damte M, Wang Y. Azithromycin for acute bronchitis: a randomised, double-blind, controlled trial. Lancet. 2002;359(9318):1648-1654. (Pubitemid 34518524)
22. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004;363(9409):600-607. (Pubitemid 38264177)
23. Sayiner A, Aytemur ZA, Cirit M, Unsal I. Systemic glucocorticoids in severe exacerbations of COPD. Chest. 2001;119(3):726-730. (Pubitemid 32197640)
24. Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest. 2007;131(1):9-19. (Pubitemid 46122969)
25. Bridevaux PO, Probst-Hensch NM, Schindler C, et al. Prevalence of airflow obstruction in smokers and never-smokers in Switzerland. Eur Respir J. 2010;36(6):1259-1269.